. 2019 Nov 12;14:200. doi: 10.1186/s13014-019-1389-7

Table 4.

Summary of currently published studies using hypofractionated radiotherapy and temozolomide for elderly patients with glioblastomas

Author	Treatment	n	Patients	OS (mo)	PFS (mo)
Minniti et al. 2009 [33]	RT 30Gy/6fr + TMZ	43	Age ≥ 70 and KPS ≥60	9.3	6.3
Uto et al. 2015 [31]	RT 35Gy/10fr + TMZ	11	Age ≥ 70	13.2	7
Minniti et al. 2012 [29]	RT40Gy/15fr + TMZ	71	Age ≥ 70 and KPS ≥60	12.4	6
Perry et al. 2017 [8]	RT40Gy/15fr	281	Age ≥ 65 and PS 0–2	7.6	3.9
Perry et al. 2017 [8]	RT40Gy/15fr + TMZ	281	Age ≥ 65 and PS 0–2	9.3	5.3
Lombardi et al. 2015 [28]	RT40Gy/15fr + TMZ	71	Age ≥ 65 and PS 0–2	13.8	N/A
Lombardi et al. 2015 [28]	RT60Gy/30fr + TMZ	166	Age ≥ 65 and PS 0–2	19.4	N/A
Chang-Halpenny et al. 2015 [25]	RT 35Gy/10fr + TMZ	29	Age ≥ 65	5.4	N/A
Chang-Halpenny et al. 2015 [25]	RT60Gy/30fr + TMZ	100	Age ≥ 65	13	N/A
Terasaki et al. 2011 [15]	RT45Gy/15fr + TMZ	26	median 61(39–79)	15.6	9.6
Lim et al. 2015 [27]	RT45Gy/15fr + TMZ	33	Age ≥ 70Age < 70 and PS ≥ 3 or biopsy or rapid growth	10.6	7.5
Harris et al. 2017 [24]	Best supportive care	31	Age ≥ 75	1.9	N/A
	RT alone*	38		6.2	N/A
	RT* + TMZ	33		13.2	N/A
Matsuda et al. 2018 [13]	RT45Gy/15fr + TMZ, Bev after recurrence	18	Age ≥ 75	20	2.5
Present study	RT45Gy/15fr + TMZ or TMZ/Bev	30	Age ≥ 75	12.9	9.9

RT Radiation therapy, TMZ Temozolomide, Bev Bevacizumab, PFS Progression free survival, OS Overall survival, KPS Karnofsky performance status, PS Performance status, N/A not available

* Radiation therapy was either hypofractionation (40Gy), or longer-course (60Gy)